Jonas Ohlsson, former CEO at Mentice, has extensive experience of the biotech industry and has held executive positions at PE Applied Biosystems, Kovalent and AstraZeneca. Significantly, Mr Ohlsson previously guided Mentice through a similar growth period to the one that Cellectricon now enters. During 2008-2009 Cellectricon will launch two large-scale screening systems that are expected to revolutionize pre-clinical pharmaceutical development.
Mattias Karlsson, former acting CEO of Cellectricon, has been appointed chief technical officer. Dr Karlsson will, in this new role, focus on managing the introduction of Cellectricon’s new and enabling screening systems.
Axel Broms, Cellectricon’s chairman, said: “The board is convinced that these appointments will secure the continued successful development of Cellectricon and strengthen the capacity as the Company is rapidly increasing its global businesses. It is with great joy we welcome Jonas Ohlsson to Cellectricon.”